5-Aminosalicylates Reduce the Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis: An Updated Meta-Analysis
نویسندگان
چکیده
BACKGROUND Although the chemopreventive effect of 5-aminosalicylates on patients with ulcerative colitis has been extensively studied, the results remain controversial. This updated review included more recent studies and evaluated the effectiveness of 5-aminosalicylates use on colorectal neoplasia prevention in patients with ulcerative colitis. METHODS Up to July 2013, we searched Medline, Embase, Web of Science, Cochrane CENTRAL, and SinoMed of China for all relevant observational studies (case-control and cohort) about the effect of 5-aminosalicylates on the risk of colorectal neoplasia among patients with ulcerative colitis. The Newcastle-Ottawa Scale was used to assess the quality of studies. Adjusted odds ratios (ORs) were extracted from each study. A random-effects model was used to generate pooled ORs and 95% confidence intervals (95%CI). Publication bias and heterogeneity were assessed. RESULTS Seventeen studies containing 1,508 cases of colorectal neoplasia and a total of 20,193 subjects published from 1994 to 2012 were analyzed. 5-aminosalicylates use was associated with a reduced risk of colorectal neoplasia in patients with ulcerative colitis (OR 0.63; 95%CI 0.48-0.84). Pooled OR of a higher average daily dose of 5-aminosalicylates (sulfasalazine ≥ 2.0 g/d, mesalamine ≥ 1.2 g/d) was 0.51 [0.35-0.75]. Pooled OR of 5-aminosalicylates use in patients with extensive ulcerative colitis was 1.00 [0.53-1.89]. CONCLUSION Our pooled results indicated that 5-aminosalicylates use was associated with a reduced risk of colorectal neoplasia in patients with ulcerative colitis, especially in the cases with a higher average daily dose of 5-aminosalicylates use. However, the chemopreventive benefit of 5-aminosalicylates use in patients with extensive ulcerative colitis was limited.
منابع مشابه
Histological inflammation increases the risk of colorectal neoplasia in ulcerative colitis: a systematic review
BACKGROUND/AIMS Ulcerative colitis (UC) patients are at greater risk for the development of colorectal neoplasia. Several individual studies have demonstrated associations between severity of histologic inflammation and colorectal neoplasia. However, a comprehensive systematic review has not been completed. We performed a systematic review and meta-analysis to explore the relationship between h...
متن کاملReview article: evolving concepts in treatment and disease modification in ulcerative colitis.
BACKGROUND More than two-thirds of ulcerative colitis patients experience at least one relapse over a period of 10 years. Treatments that reduce the likelihood of relapses also reduce the risk of long-term complications. AIM To review three topics: the current standard of treatment for ulcerative colitis, evolving concepts in treatment, and disease modification as a treatment goal of the futu...
متن کاملUlcerative Colitis-Associated Colorectal Cancer Prevention by 5-Aminosalicylates: Current Status and Perspectives
متن کامل
[Colorectal cancer in inflammatory bowel disease].
BACKGROUND Colorectal cancer is a complication of longstanding inflammatory bowel disease. The association between cancer and inflammation is best documented in ulcerative colitis, but an increased risk of cancer is also found in patients with Crohn's disease. Surveillance with colonoscopy is commonly used to detect dysplasia and early cancer in patients with in ulcerative colitis. There has be...
متن کاملUlcerative colitis: sclerosing cholangitis today, cancer tomorrow?
The relation between inflammatory bowel disease (IBD), mainly ulcerative colitis, and primary sclerosing cholangitis (PSC) is particularly close, as approximately two thirds of patients with PSC have, or will develop, ulcerative colitis, and PSC occurs in approximately 3–7% of patients with ulcerative colitis. In a large Swedish epidemiological study, approximately 5.5% of patients with extensi...
متن کامل